SDCBP2 (syndecan binding protein 2) is a phosphatidylinositol 4,5-bisphosphate (PIP2)-binding protein localized to the cytoplasm, nucleus, and plasma membrane 1. It plays roles in cell division, survival, and intracellular signaling. In cancer contexts, SDCBP2 promotes tumor progression across multiple malignancies. In lung adenocarcinoma, SDCBP2 overexpression correlates with poor prognosis and functions as a ferroptosis-related oncogene; SDCBP2 knockdown induces G0/G1 arrest, apoptosis, and reduces glutathione levels while enhancing reactive oxygen species 2. In acute myeloid leukemia, SDCBP2 is a target of the E2A transcription factor, and its downregulation suppresses proliferation and induces differentiation 3. Conversely, the SDCBP2-AS1 lncRNA (transcribed from the opposite strand) acts as a tumor suppressor in gastric cancer by binding hnRNP K to promote β-catenin degradation 4, and in ovarian and lung cancers via competing endogenous RNA mechanisms 56. Outside oncology, SDCBP2-AS1 promotes osteogenic differentiation of bone marrow mesenchymal stem cells and serves as a biomarker for postmenopausal osteoporosis through miR-361-3p regulation 7. Gene dosage imbalance from 20p13 duplications contributes to neurodevelopmental phenotypes 8.